Table 1 Characteristics of patients used to evaluate MSI status
|  | Training cohort (n = 142) | Validation cohort (n = 59) | ||||
|---|---|---|---|---|---|---|
Characteristic | MSI-H | MSS | p value | MSI-H | MSS | p value |
Age (years) | Â | Â | 1 | Â | Â | 0.738 |
 < 65 | 19 (59.37) | 65 (59.09) |  | 8 (61.54) | 32 (69.57) |  |
 ≥ 65 | 13 (40.63) | 45 (40.91) |  | 5 (38.46) | 14 (30.43) |  |
Sex | Â | Â | 0.644 | Â | Â | 0.037 |
 Male | 23 (71.88) | 84 (76.36) |  | 6 (46.15) | 36 (78.26) |  |
 Female | 9 (28.12) | 26 (23.64) |  | 7 (53.85) | 10 (21.74) |  |
Location | Â | Â | 0.007 | Â | Â | 0.015 |
 Cardia | 5 (15.63) | 40 (36.36) |  | 1 (7.69) | 18 (39.13) |  |
 Body | 6 (18.75) | 34 (30.91) |  | 4 (30.77) | 19 (41.31) |  |
 Antrum | 20 (62.50) | 32 (29.09) |  | 7 (53.85) | 8 (17.39) |  |
 Whole | 1 (3.12) | 4 (3.64) |  | 1 (7.69) | 1 (2.17) |  |
Clinical T stage | Â | Â | 0.013 | Â | Â | 0.762 |
 T3 | 13 (40.63) | 73 (66.36) |  | 7 (53.85) | 27 (58.70) |  |
 T4 | 19 (59.37) | 37 (33.64) |  | 6 (46.15) | 19 (41.30) |  |
Clinical N stage | Â | Â | 0.062 | Â | Â | 0.113 |
 N- | 17 (53.13) | 37 (33.64) |  | 10 (76.92) | 22 (47.83) |  |
 N+ | 15 (46.87) | 73 (66.36) |  | 3 (23.08) | 24 (52.17) |  |
CA 72−4 level |  |  | 0.290 |  |  | 0.187 |
 Normal | 24 (75.00) | 93 (84.55) |  | 7 (53.85) | 34 (73.91) |  |
 Abnormal | 8 (25.00) | 17 (15.45) |  | 6 (46.15) | 12 (26.09) |  |
CA 19−9 level |  |  | 0.605 |  |  | 0.357 |
 Normal | 25 (78.13) | 91 (82.73) |  | 10 (76.92) | 41 (89.13) |  |
 Abnormal | 7 (21.87) | 19 (17.27) |  | 3 (23.08) | 5 (10.87) |  |
CEA level | Â | Â | 0.443 | Â | Â | 1.00 |
 Normal | 25 (78.13) | 92 (83.64) |  | 11 (84.62) | 40 (86.96) |  |
 Abnormal | 7 (21.87) | 18 (16.36) |  | 2 (15.38) | 6 (13.04) |  |
 Radiomics score * | 0.91 (0.50, 1.22) | 1.53 (1.22, 1.87) | < 0.001 | 0.85 (0.43, 1.12) | 1.49 (0.94, 1.67) | < 0.001 |